BMEA Quote, Financials, Valuation and Earnings

Cerus has a net margin of -- compared to Biomea Fusion's net margin of -17.85%. Biomea Fusion's return on equity of -- beat Cerus's return on equity of -35.37%.

Biomea Fusion has a consensus price target of $20.00, signalling upside risk potential of 747.46%. On the other hand Cerus has an analysts' consensus of $4.67 which suggests that it could grow by 253.54%. Given that Biomea Fusion has higher upside potential than Cerus, analysts believe Biomea Fusion is more attractive than Cerus.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cerus has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.568%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cerus offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. Cerus pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than Cerus quarterly revenues of $43.2M. Biomea Fusion's net income of -$29.3M is lower than Cerus's net income of -$7.7M. Notably, Biomea Fusion's price-to-earnings ratio is -- while Cerus's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 1.32x for Cerus. Usually stocks with elevated PS ratios are considered overvalued.

Eyenovia has a net margin of -- compared to Biomea Fusion's net margin of -23665.31%. Biomea Fusion's return on equity of -- beat Eyenovia's return on equity of -676.86%.

Biomea Fusion has a consensus price target of $20.00, signalling upside risk potential of 747.46%. On the other hand Eyenovia has an analysts' consensus of $2.00 which suggests that it could fall by -18.03%. Given that Biomea Fusion has higher upside potential than Eyenovia, analysts believe Biomea Fusion is more attractive than Eyenovia.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eyenovia has a beta of 0.999, suggesting its less volatile than the S&P 500 by 0.104%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eyenovia offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. Eyenovia pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than Eyenovia quarterly revenues of $14.7K. Biomea Fusion's net income of -$29.3M is lower than Eyenovia's net income of -$3.5M. Notably, Biomea Fusion's price-to-earnings ratio is -- while Eyenovia's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 44.90x for Eyenovia. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Biomea Fusion's net margin of -49.65%. Biomea Fusion's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Biomea Fusion has a consensus price target of $20.00, signalling upside risk potential of 747.46%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 41.67%. Given that Biomea Fusion has higher upside potential than NovaBay Pharmaceuticals, analysts believe Biomea Fusion is more attractive than NovaBay Pharmaceuticals.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.305%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Biomea Fusion's net income of -$29.3M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Biomea Fusion's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Outlook Therapeutics has a net margin of -- compared to Biomea Fusion's net margin of --. Biomea Fusion's return on equity of -- beat Outlook Therapeutics's return on equity of --.

Biomea Fusion has a consensus price target of $20.00, signalling upside risk potential of 747.46%. On the other hand Outlook Therapeutics has an analysts' consensus of $8.67 which suggests that it could grow by 376.19%. Given that Biomea Fusion has higher upside potential than Outlook Therapeutics, analysts believe Biomea Fusion is more attractive than Outlook Therapeutics.

Biomea Fusion has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Outlook Therapeutics has a beta of 0.312, suggesting its less volatile than the S&P 500 by 68.826%.

Biomea Fusion has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Outlook Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Biomea Fusion pays -- of its earnings as a dividend. Outlook Therapeutics pays out -- of its earnings as a dividend.

Biomea Fusion quarterly revenues are --, which are smaller than Outlook Therapeutics quarterly revenues of --. Biomea Fusion's net income of -$29.3M is higher than Outlook Therapeutics's net income of -$46.4M. Notably, Biomea Fusion's price-to-earnings ratio is -- while Outlook Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Biomea Fusion is -- versus 5.83x for Outlook Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.